Gujarat Themis Biosyn plans a cash raise. It hasn't named the price or the buyer.
FY26 results are routine. The board's separate approval for a preferential equity issue to non-promoters is not.
— 5 earlier stories on Gujarat Themis Biosyn Ltd. →What's new
- Board approved FY26 audited results: ₹168.5 cr revenue, ₹46.7 cr net profit.
- Final dividend of ₹0.67 per share recommended.
- Board cleared a preferential equity issue to non-promoters; quantum and pricing pending.
Why this matters
The financial results and dividend are standard compliance items. The preferential issue approval is a blank cheque for a capital raise and dilution. The board has greenlit the move without setting the terms, leaving the impact on existing shareholders undefined.
What we're watching
- Identity of the non-promoter investor(s) and the size of the raise.
- The discount, if any, to market price at which new shares will be issued.
- Shareholder vote and regulatory timeline for the allotment.
The full read
Gujarat Themis Biosyn's FY26 results are straightforward: ₹168.5 crore in revenue, ₹46.7 crore in profit, a ₹0.67 dividend. None of that moves the needle. The separate board approval for a preferential issue to non-promoters does. It is a green light for a new equity raise, but one without a fixed price, a fixed size, or a named buyer. That creates a specific risk: the terms will be set later, and existing shareholders will have to live with them. The company now begins the process of seeking approvals for a deal whose central numbers are still blank.
Questions answered
- What were the two distinct approvals at the Gujarat Themis board meeting?
- First, it signed off on routine FY26 financial results and a final dividend. Second, it approved a proposal for a preferential equity issue to non-promoter investors.
- Why is the preferential issue notable if the terms are undecided?
- It signals a planned capital infusion that will dilute existing shareholders. By approving the structure without the quantum or pricing, the board has committed to a raise whose cost is still unknown.
- What is the next step for the preferential allotment?
- The company must now secure shareholder and regulatory approvals. The specific details of the issue size, pricing, and investor will be determined later.
Gujarat Themis Biosyn Ltd.
Latest quarter · Mar 2026
Strength & growth
Story so far
All notes on GUJTHEM →- 25 May 2026 · 3:09 PM IST Gujarat Themis Biosyn plans a cash raise. It hasn't named the price or the buyer.
- 7d ago Gujarat Themis placed on rating watch; acquisitions cost 10x net worth
- 22d ago Gujarat Themis promoter stake is now tied to third-party debt
- 47d ago Gujarat Themis will dilute a fifth of itself for a ¥21.5bn Japan deal
- 51d ago Gujarat Themis Biosyn to raise equity for ¥21.5 bn Japan deal